Figure S1. Dose-dependent inhibition of CK2 catalytic activity by TBB and Emodin. Cell lysates of MEFs were immunoprecipitated with anti-CK2α antibody, and assayed for CK2 activity in the presence of different concentrations of TBB (5-100 μM) (A) or Emodin (5-100 μM) (B). The value of the untreated sample was arbitrarily set as 100%. Experiments were performed in triplicate, and error bars show ± S.D..

Figure S2. Co-immunoprecipitation of CK2 with endogenous JAK2. Lysates of MEFs (**A-B**), MDA-MB-231 (**C**) and primary astrocytes (**D**) were immunoprecipitated (IP) with CK2α, JAK2, normal goat IgG (G-IgG, negative control), or normal rabbit IgG (R-IgG, negative control) as indicated, and then immunoblotted (IB) with the indicated antibodies.

Figure S3. CK2 does not associate with IFNGR1. Lysates of γ2A-JAK2 cells were immunoprecipitated with anti-IFNGR1 antibody, and immunoblotted with the indicated antibodies.

Figure S4. Inhibition of JAK2 by P6 does not affect CK2 catalytic activity. MEFs were treated with different concentrations of P6 (0.1-10 μM). Cell lysates were

immunoprecipitated with anti-CK2α antibody, and assayed for CK2 activity. Experiments were performed in triplicate, and error bars show ± S.D..

Figure S1


A
120
100
80
60
40
20
0
CK2 Catalytic Activity (%)
UT
5
25
50
100
TBB (μM)
B
120
100
80
60
40
20
0
CK2 Catalytic Activity (%)
UT
5
10
25
50
100
Emodin (μM)

Figure S2


A
IP: CK2a G-IgG
IB: JAK2
CK2a
MEF
B
IP: JAK2 R-IgG
IB: CK2a
JAK2
MEF
C
IP: JAK2 R-IgG
IB: CK2a
JAK2
MDA-MB-231
D
IP: JAK2 R-IgG
IB: CK2a
JAK2
Primary astrocytes

Figure S3



Figure S4